Advertisement

New Drug Approved for Chronic Lymphocytic Leukemia — Physician’s First Watch

Medical News |
February 13, 2014

New Drug Approved for Chronic Lymphocytic Leukemia

By Kristin J. Kelley

The FDA has granted accelerated approval of ibrutinib (marketed as Imbruvica) for patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.

Approval for the drug — which blocks the enzyme needed for cancer growth (Bruton's tyrosine kinase) — was based on a clinical trial of 48 CLL patients who, on average, were treated with four previous therapies. All participants received ibrutinib, and the cancer responded in almost 58%.

Ibrutinib was approved to treat mantle cell lymphoma in November 2013.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement